© 2021 MJH Life Sciences and Contemporary Pediatrics. All rights reserved.
© 2021 MJH Life Sciences™ and Contemporary Pediatrics. All rights reserved.
July 22, 2021
AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is available for prescription to help provide rapid and extended duration of attention-deficit/hyperactivity disorder (ADHD) symptoms.
July 21, 2021
As more extremely preterm infants survive delivery, a study examines whether the advances that allowed for that survival also improve neurodevelopmental outcomes.
July 20, 2021
Although too much screen time isn’t beneficial to any child, could the developmental and behavioral impact of this be exacerbated in a child who was born at less than 28 weeks?
July 01, 2021
A study examines the effect of after-school activity participation on a child's attention-deficit/hyperactivity disorder (ADHD) severity.
June 18, 2021
Global prevalence of autism spectrum disorder is 1% to 2%, but little research has been done in non-White populations. An investigation offers some much-needed insight.
June 09, 2021
Stimulants are recommended as the first-line treatment for attention-deficit/hyperactivity disorder (ADHD). A study examines whether α2-adrenergic agonists could be effective as well.
June 02, 2021
The US Food and Drug Administration has given marketing authorization to Cognoa, Inc. for their device to aid in the diagnosis of autism spectrum disorder (ASD).
May 21, 2021
A study examines if promoting positive behaviors including masking leads to improved face covering in children with autism spectrum disorder and/or attention-deficit/hyperactivity disorder.
May 04, 2021
Is there value in predictive testing for autism spectrum disorder (ASD)? A study examines the ethics.
April 06, 2021
The US Food and Drug Administration (FDA) approves first novel non-stimulant medication to treat attention-deficit/hyperactivity disorder (ADHD) in children in a decade.